High-dose treatment with somatostatin analogues in neuroendocrine tumours

Modica, Roberta; Ramundo, Valeria; Marciello, Francesca; Marotta, Vincenzo; Pizza, Genoveffa; Carratù, A; Roseto, Chiara de Luca di; Buonomano, Pasqualina; Giordano, Carla; Trimarchi, Francesco; Colao, Annamaria; Faggiano, Antongiulio

doi:10.1530/endoabs.37.ep1132

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results from the PubMed database and congress abstract search and screening are presented in Figure . The review consisted of 40 publications, including 27 full‐length publications and 13 congress abstracts (Tables and ) . Thirty‐six (90%) of the publications reported on studies performed in Europe, three involved centers in Europe, the U.S., and India (including the two subgroup analyses studies and an open‐label extension [OLE] study from the core CLARINET study), one was performed in the U.S., and one was performed in Israel.…”

Section: Resultsmentioning

confidence: 99%

“…Safety and tolerability during studies of antitumor effects in NET patients was reported in 33 of the 40 publications, of which 23 were full‐length articles and 11 were congress abstracts (Table ) . A large body of evidence also exists from clinical trials and clinical practice on patients with acromegaly or carcinoid syndrome that supports the safety and tolerability of lanreotide Autogel, but this is outside the scope of this review.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review

Michael

Garcia-Carbonero

Weber³

et al. 2017

The Oncologist

View full text Add to dashboard Cite

Current clinical evidence shows that lanreotide Autogel has good antiproliferative activity with favorable safety and tolerability in patients with GEP-NETs, suggesting it should be considered as an early first-line treatment in this population. Further studies are needed to assess the potential benefits of higher doses and the use of lanreotide Autogel in combination therapy and as maintenance therapy in the absence of disease progression following other therapies. 2017;22:272-285 IMPLICATIONS FOR PRACTICE: This review presents the current clinical evidence for the antiproliferative activity of lanreotide Autogel in patients with midgut or pancreatic neuroendocrine tumors (NETs) and shows its effectiveness, safety, and tolerability in these patient populations. By systematically presenting all the clinical evidence, the review adds to existing publications by discussing results in a broad range of settings. The review also indicates future directions for investigation of the use of lanreotide Autogel in NETs originating in other locations, in combination therapy, or as maintenance therapy in progressive disease.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review

Michael

Garcia-Carbonero

Weber³

et al. 2017

The Oncologist

View full text Add to dashboard Cite

show abstract

“… 38 A retrospective study of 118 Italian patients reported that 18% of patients received high-frequency SSA, with 15 of these patients treated with octreotide and six receiving lanreotide, but the proportions among the original 118 patients were not reported. 39 An observational study of 273 patients across eight European countries who received lanreotide reported that 98% received doses between 60 and 120 mg and 93% received injections every 4 weeks. The dosing for the small proportion not following US-indicated dosing was not described.…”

Section: Discussionmentioning

confidence: 99%

Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals

Ortendahl¹,

Pulgar²,

Mirakhur³

et al. 2017

CEOR

View full text Add to dashboard Cite

ObjectiveWith the introduction of new therapies, hospitals have to plan spending limited resources in a cost-effective manner. To assist in identifying the optimal treatment for patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors, budget impact modeling was used to estimate the financial implications of adoption and diffusion of somatostatin analogs (SSAs).Patients and methodsA hypothetical cohort of 500 gastroenteropancreatic neuroendocrine tumor patients was assessed in an economic model, with the proportion with metastatic disease treated with an SSA estimated using published data. Drug acquisition, preparation, and administration costs were based on national pricing databases and published literature. Octreotide dosing was based on published estimates of real-world data, whereas for lanreotide, real-world dosing was unavailable and we therefore used the highest indicated dosing. Alternative scenarios reflecting the proportion of patients receiving lanreotide or octreotide were considered to estimate the incremental budget impact to the hospital.ResultsIn the base case, 313 of the initial 500 gastroenteropancreatic neuroendocrine tumor patients were treated with an SSA. The model-predicted per-patient cost was US$83,473 for lanreotide and US$89,673 for octreotide. With a hypothetical increase in lanreotide utilization from 5% to 30% of this population, the annual model-projected hospital costs decreased by US$488,615. When varying the inputs in one-way sensitivity analyses, the results were most sensitive to changes in dosing assumptions.ConclusionResults suggest that factors beyond drug acquisition cost can influence the budget impact to a hospital. When considering preparation and administration time, and real-world dosing, use of lanreotide has the potential to reduce health care expenditures associated with metastatic gastroenteropancreatic neuroendocrine tumor treatments.

show abstract

Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review

et al. 2017

View full text Add to dashboard Cite

The current evidence indicates that escalated-dose somatostatin analogues are well-tolerated in patients with gastroenteropancreatic neuroendocrine tumours, with significant rates of disease control but low rates of tumour response. It was difficult to judge the exact rate of biochemical response or symptomatic improvement. There is a need for large, prospective studies investigating the role of escalated-dose somatostatin analogues in the treatment of metastatic gastroenteropancreatic neuroendocrine tumours.

show abstract

High-dose treatment with somatostatin analogues in neuroendocrine tumours

Cited by 3 publications

References 0 publications

The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review

The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review

Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals

Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review

Contact Info

Product

Resources

About